.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Research indicates that Ischemia-Modified Albumin levels significantly increase as humans age. Specifically, a recent study examined serum oxidative stress markers across young, middle-aged, and elderly populations. Consequently, findings suggest that advanced age correlates with higher IMA concentrations. This reflects potential systemic oxidative changes occurring over the lifespan.
The investigators utilized the albumin cobalt binding assay to measure the protein's metal-binding capacity. In addition, they calculated the IMA/albumin ratio (IMAR) to provide a more standardized assessment. Notably, the elderly group (73-99 years) exhibited markedly higher values compared to younger cohorts. Therefore, aging independently influences the structural integrity of serum albumin through oxidative modifications.
Clinicians must account for these age-related baseline shifts when evaluating acute conditions. Using a single cutoff for all adults may lead to diagnostic inaccuracies. Furthermore, the IMA/albumin ratio serves as a sensitive indicator of chronic oxidative stress in older patients. However, further research is required to establish definitive reference ranges for diverse populations.
As individuals age, systemic oxidative stress naturally increases while antioxidant defenses decline. This environmental change causes the N-terminal end of albumin to modify, leading to higher Ischemia-Modified Albumin levels.
The IMAR is a calculated value that adjusts the IMA level relative to the total serum albumin concentration. It provides a more accurate representation of oxidative stress, especially in patients with varying albumin levels.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional opinion. Always seek the advice of a qualified healthcare provider with any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Teselkin YO et al. The Level of Ischemia-Modified Albumin in Healthy Individuals of Different Age Groups. Bull Exp Biol Med. 2026 Mar 10. doi: 10.1007/s10517-026-06607-y. PMID: 41806345.
Sbarouni E et al. Ischemia-modified albumin: an overview. Hellenic J Cardiol. 2011;52(4):298-302.
Piwowar A. Ischemia-modified albumin (IMA) – a marker with many faces. Adv Clin Exp Med. 2010;19(4):411-421.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
New research highlights how Ischemia-Modified Albumin (IMA) and the IMA/albumin ratio (IMAR) increase significantly in elderly and older populations....
6 months ago
A 2026 meta-analysis evaluates PDE5 inhibitors in advanced ILD with severe gas exchange impairment. While overall mortality was not significantly reduced, a targeted subgroup with pulmonary hypertension showed a 49% risk reduction, underscoring the necessity of precise hemodynamic phenotyping.
Today
A multicentre RCT in China shows that the PAICS AI system significantly boosts sonographer sensitivity in detecting fetal intracranial malformations by 8.7% without compromising specificity, offering promising diagnostic support for prenatal neurosonography.
Today
The Supreme Court questioned FSSAI's phased warning approach, urging single-phase implementation for foods exceeding limits in any nutrient of concern. Backed by ICMR-NIN recommendations, the proposed red hexagonal warnings target added sugar, salt, and fat to combat India's escalating chronic disease epidemic.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
A comparative analysis shows that older age, elevated blood glucose, and abdominal adiposity are primary drivers of hypertension. Comprehensive evaluation of cardiometabolic risk profiles enables clinicians to detect overlapping metabolic dysfunctions early and optimize targeted prevention strategies.
Today
